Merck Q1 Loss Masks Strong Sales Growth

Q1 Financial Highlights

Merck & Co reported a net loss for the first quarter, a result driven by a significant one-time charge related to its acquisition of Cidara Therapeutics. Despite the loss on paper, the pharmaceutical giant saw a 5% increase in product sales, indicating strong underlying operational performance.

Performance Overview

The company's revenue for the quarter rose to $16.3 billion, surpassing the average Wall Street estimate of $15.8 billion. The adjusted loss was $1.28 per share, which was narrower than the anticipated loss of $1.51 per share. This figure includes the substantial $3.62 per share charge from the acquisition. Keytruda, its blockbuster cancer immunotherapy, continued its strong performance with sales rising 12% to $8 billion.

Segment Performance and Economic Impact

Growth was primarily fueled by oncology and respiratory drugs. Sales of the lung disease treatment Winrevair surged 88% to $525 million. The animal health division also provided a bright spot, with sales jumping 13% to $1.8 billion. However, sales for the diabetes drug Januvia and the HPV vaccine Gardasil saw declines. In response to the strong sales figures, Merck raised its full-year 2026 profit forecast to a range of $5.04 to $5.16 per share.

Summary and Outlook

While the acquisition charge led to a statutory loss, Merck's core business demonstrates robust health and growth. The upward revision of its full-year guidance signals confidence from management. Investors will likely focus on the sustained sales momentum of key products and the successful integration of recent acquisitions moving forward.

FAQ

Q: Why did Merck report a financial loss despite a 5% increase in sales?
A: The loss was due to a one-time, non-recurring charge of $3.62 per share associated with the acquisition of antiviral drug maker Cidara Therapeutics.

Q: Which products were the main drivers of Merck's revenue growth?
A: The primary growth drivers were the cancer drug Keytruda, with sales up 12%, and the lung disease drug Winrevair, with sales increasing by 88%.

Source: Investing.com